+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neurological Biomarkers Market Research Report by Type, Application, End-user, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 229 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 5454976
UP TO OFF until Dec 31st 2022
The Global Neurological Biomarkers Market size was estimated at USD 6,936.10 million in 2021, USD 7,891.21 million in 2022, and is projected to grow at a CAGR of 13.94% to reach USD 15,182.18 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Neurological Biomarkers to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Genomic, Imaging, Metabolomic, and Proteomic.
  • Based on Application, the market was studied across Alzheimer’s Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson’s Disease.
  • Based on End-user, the market was studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Neurological Biomarkers market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neurological Biomarkers Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neurological Biomarkers Market, including AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Inc., Athena Diagnostics Inc, Banyan Biomarkers, Inc., Bio-Rad Laboratories, Inc., Diagenic ASA, Imagilys, Invicro. LLC., IXICO plc, Myriad RBM, Proteome Sciences Plc, Psynova Neurotech, Qiagen N.V., Quanterix Corporation, Sigma-Aldrich, Inc, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neurological Biomarkers Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neurological Biomarkers Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neurological Biomarkers Market?
4. What is the competitive strategic window for opportunities in the Global Neurological Biomarkers Market?
5. What are the technology trends and regulatory frameworks in the Global Neurological Biomarkers Market?
6. What is the market share of the leading vendors in the Global Neurological Biomarkers Market?
7. What modes and strategic moves are considered suitable for entering the Global Neurological Biomarkers Market?
Frequently Asked Questions about the Global Neurological Biomarkers Market

What is the estimated value of the Global Neurological Biomarkers Market?

The Global Neurological Biomarkers Market was estimated to be valued at $6936.1 Million in 2021.

What is the growth rate of the Global Neurological Biomarkers Market?

The growth rate of the Global Neurological Biomarkers Market is 13.9%, with an estimated value of $15182.18 Million by 2027.

What is the forecasted size of the Global Neurological Biomarkers Market?

The Global Neurological Biomarkers Market is estimated to be worth $15182.18 Million by 2027.

Who are the key companies in the Global Neurological Biomarkers Market?

Key companies in the Global Neurological Biomarkers Market include AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Inc., Athena Diagnostics Inc, Banyan Biomarkers, Inc., Bio, Rad Laboratories, Inc. and Imagilys.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of neurological disorders
5.1.1.2. Demand for cost-effective and non-invasive diagnostic system
5.1.1.3. Increasing preferences on early diagnosis & preventive treatment
5.1.2. Restraints
5.1.2.1. Stringent government regulations for approvals
5.1.3. Opportunities
5.1.3.1. Growing R&D focus for advancements in biomarkers
5.1.3.2. Emerging single-cell biosensors
5.1.3.3. Growth of low-cost clinical trials in developing countries
5.1.4. Challenges
5.1.4.1. Ethical problems and acceptance issues of neurological disorders
5.2. Cumulative Impact of COVID-19
6. Neurological Biomarkers Market, by Type
6.1. Introduction
6.2. Genomic
6.3. Imaging
6.4. Metabolomic
6.5. Proteomic
7. Neurological Biomarkers Market, by Application
7.1. Introduction
7.2. Alzheimer’s Disease
7.3. Autism Spectrum Disorders
7.4. Multiple Sclerosis
7.5. Parkinson’s Disease
8. Neurological Biomarkers Market, by End-user
8.1. Introduction
8.2. Hospital Laboratories
8.3. Independent Clinical Diagnostic Centers
8.4. Research Organizations
9. Americas Neurological Biomarkers Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Neurological Biomarkers Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Neurological Biomarkers Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbaStar MDx, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abbott Laboratories
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Acumen Pharmaceuticals
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Alseres Pharmaceuticals, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Athena Diagnostics Inc
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Banyan Biomarkers, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bio-Rad Laboratories, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Diagenic ASA
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Imagilys
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Invicro. LLC.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. IXICO plc
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Myriad RBM
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Proteome Sciences Plc
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Psynova Neurotech
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Qiagen N.V.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Quanterix Corporation
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Sigma-Aldrich, Inc
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Thermo Fisher Scientific Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2027
FIGURE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, 2018-2027 (USD MILLION)
FIGURE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, 2018-2027 (USD MILLION)
FIGURE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, 2018-2027 (USD MILLION)
FIGURE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2027 (USD MILLION)
FIGURE 24. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, 2018-2027 (USD MILLION)
FIGURE 25. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USER, 2027
FIGURE 28. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2027 (USD MILLION)
FIGURE 29. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, 2018-2027 (USD MILLION)
FIGURE 30. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2027 (USD MILLION)
FIGURE 31. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 33. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 34. AMERICAS NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 35. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 36. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 38. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 39. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 41. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 42. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 43. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 45. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 46. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 47. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 55. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 56. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 57. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 63. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 71. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 72. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 73. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 74. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 75. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 76. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 77. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 78. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 79. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 80. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 81. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 82. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 83. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 84. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 85. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 86. GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2027 (USD MILLION)
TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, 2018-2027 (USD MILLION)
TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, 2018-2027 (USD MILLION)
TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2027 (USD MILLION)
TABLE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, 2018-2027 (USD MILLION)
TABLE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2027 (USD MILLION)
TABLE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2027 (USD MILLION)
TABLE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, 2018-2027 (USD MILLION)
TABLE 24. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2027 (USD MILLION)
TABLE 25. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2027 (USD MILLION)
TABLE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2027 (USD MILLION)
TABLE 27. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2027 (USD MILLION)
TABLE 28. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2027 (USD MILLION)
TABLE 29. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, 2018-2027 (USD MILLION)
TABLE 30. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2027 (USD MILLION)
TABLE 31. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2027 (USD MILLION)
TABLE 32. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 33. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2027 (USD MILLION)
TABLE 34. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 35. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2027 (USD MILLION)
TABLE 36. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, 2018-2027 (USD MILLION)
TABLE 37. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2027 (USD MILLION)
TABLE 38. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2027 (USD MILLION)
TABLE 39. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2027 (USD MILLION)
TABLE 40. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2027 (USD MILLION)
TABLE 41. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2027 (USD MILLION)
TABLE 42. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 44. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 45. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 46. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 47. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 48. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 49. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 50. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 51. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 52. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 53. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 54. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 55. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 56. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 57. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 58. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 59. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 60. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 61. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 62. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 63. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 64. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 65. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 66. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 67. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 68. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 69. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 70. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 72. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 73. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 74. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 75. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 76. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 77. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 78. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 79. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 80. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 81. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 82. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 83. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 84. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 85. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 86. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 87. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 88. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 89. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 90. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 91. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 92. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 93. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 94. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 95. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 96. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 97. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 98. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 99. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 100. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 101. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 102. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 103. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 104. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 105. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 106. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 107. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 108. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 109. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 110. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 111. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 112. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 113. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 114. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 115. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 116. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 117. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 118. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 119. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 120. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 126. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 127. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 128. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 129. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 130. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 131. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 132. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 133. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 134. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 135. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 136. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 137. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 138. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 139. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 140. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 141. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 142. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 143. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 144. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 145. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 146. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 147. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 149. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 150. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 151. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 153. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 154. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 155. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 156. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 157. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 158. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 159. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 160. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 161. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 162. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 163. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 164. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 165. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 166. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 167. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 168. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 169. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 170. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 171. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 173. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 174. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 175. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 176. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 177. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 178. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 179. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 180. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 181. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 182. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 183. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 184. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 185. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 186. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 187. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 188. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 189. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 190. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 191. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 192. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 193. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 194. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 195. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 196. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 197. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 198. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 199. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 200. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 201. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 206. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 207. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 208. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 209. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 210. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 211. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 212. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 213. GLOBAL NEUROLOGICAL BIOMARKERS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 214. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 215. GLOBAL NEUROLOGICAL BIOMARKERS MARKET MERGER & ACQUISITION
TABLE 216. GLOBAL NEUROLOGICAL BIOMARKERS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 217. GLOBAL NEUROLOGICAL BIOMARKERS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 218. GLOBAL NEUROLOGICAL BIOMARKERS MARKET INVESTMENT & FUNDING
TABLE 219. GLOBAL NEUROLOGICAL BIOMARKERS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 220. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbaStar MDx, Inc.
  • Abbott Laboratories
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals, Inc.
  • Athena Diagnostics Inc
  • Banyan Biomarkers, Inc.
  • Bio-Rad Laboratories, Inc.
  • Diagenic ASA
  • Imagilys
  • Invicro. LLC.
  • IXICO plc
  • Myriad RBM
  • Proteome Sciences Plc
  • Psynova Neurotech
  • Qiagen N.V.
  • Quanterix Corporation
  • Sigma-Aldrich, Inc
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...